RHYTHM PHARMACEUTICALS, INC. Deferred Tax Assets, Operating Loss Carryforwards, State and Local
RHYTHM PHARMACEUTICALS, INC. (RYTM) had Deferred Tax Assets, Operating Loss Carryforwards, State and Local of $807.90 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Operating Loss Carryforwards, Components
us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal · last filed 2026-02-26
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards, State and Local $807.90M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards, State and Local $694.03M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards, State and Local $597.95M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards, State and Local $484.61M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards, State and Local |
|---|---|
| 2025-12-31 | $807.90M 10-K · filed 2026-02-26 |
| 2024-12-31 | $694.03M 10-K · filed 2025-02-28 |
| 2023-12-31 | $597.95M 10-K · filed 2024-02-29 |
| 2022-12-31 | $484.61M 10-K · filed 2023-03-01 |
| 2021-12-31 | $385.09M 10-K · filed 2022-03-01 |
| 2020-12-31 | $351.19M 10-K · filed 2021-03-01 |
| 2019-12-31 | $241.31M 10-K · filed 2020-03-02 |
| 2018-12-31 | $113.38M 10-K · filed 2019-03-08 |
| 2017-12-31 | $3.76M 8-K · filed 2018-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |